Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

May 28, 2024

Study Completion Date

December 30, 2024

Conditions
Sedation
Interventions
DRUG

Isoflurane

Inhaled isoflurane administered by Sedaconda ACD-S

DRUG

Propofol

Intravenous infusion of propofol

Trial Locations (16)

10032

The New York and Presbyterian Hospital, New York

19107

Thomas Jefferson University, Philadelphia

23284

Virginia Commonwealth University, Richmond

33146

University of Miami, Coral Gables

43210

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

60612

Rush University Medical Center, Chicago

77030

Memorial Hermann Health Services, Houston

90095

University of California, Los Angeles, Los Angeles

90807

Memorial Health Services, Long Beach

92023

University of California, San Diego, San Diego

94063

Stanford University, Redwood City

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

08103

The Cooper Health System, Camden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sedana Medical

INDUSTRY

NCT05327296 - Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) | Biotech Hunter | Biotech Hunter